China's Vaccine Diplomacy: The Brazil Deal That Wasn't Quite a Deal
The strongest weakness in Wendover Productions' March 2021 investigation is not its suggestion that China used vaccines to build influence. That strategy is credible, and some of the evidence is compelling. The problem is that the video turns suspicious timing, diplomatic alignment and selective access into a stronger account of government bargaining than its individual cases establish.
Two details deserve particular scrutiny: Brazil's supposedly sudden reversal on Huawei and Paraguay's exclusion from Chinese vaccine supplies. Both look different when the missing chronology and diplomatic qualifications are restored.
Brazil: the timeline runs ahead of the evidence
Wendover describes Fábio Faria's February 2021 visit to Beijing, his meeting with Huawei executives, his request for vaccines, and a subsequent Brazilian decision allowing Huawei into the 5G auction. The sequence is presented as a possible exchange: vaccines for telecommunications access.
There is a serious chronological problem.
On January 16, 2021, more than three weeks before Faria's February 11 visit to Huawei, Reuters reported that Bolsonaro's government would not seek to exclude Huawei from Brazil's 5G network auctions. The reported reasons included resistance from Brazil's telecommunications industry, the cost of replacing existing Huawei equipment, and the departure of Donald Trump from the White House. Huawei already supplied approximately 50% of Brazil's existing 3G and 4G network equipment.
Investing.com
On February 25, Brazil's telecommunications regulator, Anatel, approved auction rules without restrictions on Huawei as an equipment supplier. This was a regulatory decision following a policy direction already reported in January, not convincing evidence of a new concession made after Faria's Beijing meeting.
Investing.com
There is another important distinction. On March 9, Faria told Brazil's Chamber of Deputies that Huawei did not meet the requirements for a separate, secure government 5G network serving the executive, Congress and judiciary. The commercial telecommunications network and the government's private network were two different projects with different eligibility rules.
Portal da Câmara dos Deputados
Wendover compresses these developments into one apparent reversal. That makes the Huawei story considerably more persuasive than the chronology warrants.
The minister's journey also deserves more context. Brazil officially called it Mission 5G, a tour of major telecommunications manufacturers in Europe and Asia. On February 4, Faria visited Ericsson in Sweden and appealed to Marcus Wallenberg, an investor connected to both Ericsson and AstraZeneca, to help Brazil obtain additional vaccine doses and ingredients. A subsequent academic study also records that Faria approached several telecommunications companies, including European firms, for vaccine assistance.
Ministério das Comunicações+1
His vaccine request to Huawei therefore occurred within a broader international procurement effort. It was not necessarily an exceptional arrangement between Huawei and the Brazilian government.
A 2024 academic analysis does interpret the sequence as Chinese linkage politics, potentially helping Huawei overcome opposition in Brazil. But that study also acknowledges that vaccine access alone cannot explain the country's change in direction. Domestic political divisions and commercial interests mattered.
SciELO
I am not ruling out Chinese influence. I am rejecting the stronger implication that this particular sequence establishes a vaccine-for-Huawei bargain.
The distinction matters. A government can exploit an existing policy debate without having purchased the outcome.
Paraguay: the most revealing contemporary evidence is missing
Wendover says Paraguay's absence from China's vaccine recipients is easy to explain: Paraguay recognized Taiwan. It also reports that no country recognizing Taiwan had received Chinese vaccines.
But something exceptionally relevant happened just before the video was released.
On March 24, 2021, The Guardian reported that Paraguay's Foreign Ministry had accused unofficial intermediaries of offering access to Chinese vaccines in exchange for breaking diplomatic relations with Taiwan.
The qualification was crucial. Paraguay said the intermediaries had no official status and that their connections to the Chinese government had not been established. Foreign Minister Euclides Acevedo rejected political conditions on vaccine purchases. Beijing denied involvement and described the allegations as disinformation.
The Guardian+1
The video appeared on March 26. This allegation was already public.
Wendover did not need to accept Paraguay's accusation as proven. But it should have explained it. Instead, the video presents the absence of Paraguay as an almost self-explanatory consequence of its Taiwan policy.
That removes the most important distinction in the story: an alleged attempt by intermediaries to impose political conditions is not the same thing as an established instruction from Beijing.
The omission matters even more because later research produced substantial evidence of political selection.
A 2024 World Development study by Angela Tritto, Hazwan Haini and Hongsen Wu found that countries supporting China's positions on Hong Kong and Xinjiang at the United Nations received substantially more Chinese medical assistance. Depending on the political position examined, the researchers found 205% and 166% higher vaccine donations than among countries taking contrary positions. The association was even stronger for commercial vaccine trade. These are statistical relationships, not proof that every shipment carried political conditions, but they make the geopolitical pattern difficult to dismiss.
ScienceDirect
A February 2026 study in International Studies Quarterly provides another important finding. Its analysis found that no country recognizing Taiwan received Chinese vaccine doses during the period studied. Nicaragua received 200,000 donated Sinopharm doses just four days after severing diplomatic relations with Taiwan in December 2021.
OUP Academic+1
There is a methodological qualification. The 2026 study's statistical model is explicitly descriptive rather than causal. Taiwan recognition was significantly associated with lower overall Chinese vaccine supply and exports, but the relationship was not statistically significant when donations alone were examined. The Nicaragua sequence provides additional evidence, but timing cannot independently establish why the government changed its diplomatic position.
OUP Academic+1
Indeed, a 2023 study by Detlef Nolte in International Politics reached a different conclusion about Nicaragua. Nolte argued that the country's diplomatic switch was driven primarily by the Ortega government's international isolation and increasing US pressure and sanctions, rather than Chinese vaccine diplomacy. He also found that China's campaign failed to displace Taiwan's influence significantly in Latin America.
Springer Nature Link
These findings do not absolve Beijing. They establish something more precise: political considerations influenced vaccine distribution, but the extent to which vaccine access actually caused governments to change policy remains contested.
The donation story hides the commercial business
The video devotes considerable attention to China's donated vaccine shipments. It describes small allocations to Mongolia, Sri Lanka, Algeria, Zimbabwe and other countries as opportunities to generate publicity and encourage future purchases.
That is a reasonable interpretation. But it leaves out a critical denominator.
Research by Pippa Morgan, published by Cambridge University Press, found that approximately 90% of Chinese-made vaccine doses delivered to the Global South during the first six months of 2021 were commercial sales. Only 10% were donations. The major exporters included Sinovac, Sinopharm and CanSino.
Cambridge
This changes the picture.
China's vaccine expansion was not principally a programme of free gifts. It was a combination of commercial contracts, state support, international clinical-trial partnerships and selective donations.
Morgan found that market forces and clinical-trial partnerships were important drivers of commercial distribution. Countries hosting trials subsequently became potential customers and manufacturing partners.
Detlef Nolte's research on Latin America adds another revealing detail: Chinese embassy officials sometimes appeared at airport ceremonies for commercially purchased vaccines, creating the impression that shipments were government donations. Small gifts could also encourage much larger subsequent purchases.
Springer Nature Link+1
That is a more sophisticated diplomatic mechanism than simply handing out free doses.
The 2024 World Development findings reinforce the point: political alignment was associated even more strongly with vaccine trade than with donations. Commercial access itself could carry geopolitical significance.
ScienceDirect
Wendover mentions commercial orders, but never gives readers the overall proportion of sales versus donations. Without that figure, the audience sees the highly visible diplomatic gifts without understanding the much larger commercial operation behind them.
Even the efficacy comparison needs qualification
Wendover contrasts approximately 95% efficacy for Pfizer and Moderna with figures of 50–83% for Chinese vaccines.
The numbers have a factual basis, but they are not directly interchangeable.
For example, WHO reported 51% efficacy against symptomatic infection for Sinovac in its Brazilian Phase III trial, but 100% against severe disease, with a very wide confidence interval. Its Turkish trial reported 83.5% efficacy against symptomatic infection. Pfizer's 95% figure came from a separate trial using its own primary endpoint and follow-up conditions. Sinopharm's reported efficacy against symptomatic infection was 79%.
IRIS+2
These were different studies, conducted in different populations and circumstances. Comparing headline percentages without explaining the differences risks turning a complicated scientific question into a simple league table.
The broad argument that some countries preferred earlier access to Chinese vaccines despite higher reported efficacy from Western alternatives remains plausible. The comparison simply deserves more care than the video gives it.
The stronger evidence is in the diplomatic record
There are better examples of Chinese vaccine diplomacy than the Brazil episode.
On February 10, 2021, Chinese Foreign Minister Wang Yi announced 200,000 doses of emergency vaccine assistance for Algeria. In the same official account of the conversation, he explicitly recalled Algeria's contribution to China's recovery of its United Nations seat 50 years earlier and called for stronger cooperation through the Belt and Road Initiative.
The State Council of China
This is documented diplomatic messaging. It establishes that Beijing presented vaccine assistance within a relationship built on historical political support and strategic cooperation. It does not establish that Algeria's donation was conditional on a particular vote or concession.
That distinction is important because the subsequent research is considerably stronger than the video's original collection of anecdotes. The 2024 and 2026 studies identify measurable relationships between political alignment and vaccine distribution. They give the central argument a firmer foundation than the suggestion that two events occurring close together must have been connected.
The more convincing investigation would examine who received vaccines, who was excluded, how commercial contracts were allocated, what political relationships predicted access, and whether governments changed their positions afterward.
Those questions produce evidence. A dramatic sequence of photographs and diplomatic meetings does not.
Closing verdict
Wendover identified a real instrument of Chinese foreign policy. Vaccine supply became a means of rewarding strategic partners, building commercial relationships and potentially pressuring governments that maintained diplomatic relations with Taiwan.
But its Brazil example is chronologically misleading, its Paraguay discussion omits a crucial contemporary allegation and its donation narrative lacks the commercial denominator necessary to understand the scale of the operation.
The later evidence makes the broader argument stronger, not weaker. It also points toward a more consequential interpretation: China did not need to negotiate an explicit exchange every time it distributed vaccines. Control over scarce supply, commercial access and the decision to withhold assistance could themselves become instruments of foreign policy.
That is the story worth investigating. Wendover came close to it, but its most memorable example was never established to the standard its argument deserved.
References
1. China's Vaccine Diplomacy — Wendover Productions, March 26, 2021. The original video and its claims concerning Brazil, Paraguay, Algeria and international vaccine distribution.
2. Brazil's Bolsonaro to allow China's Huawei in 5G auctions — Reuters, January 16, 2021. Establishes that Brazil's reported decision not to exclude Huawei preceded Faria's Beijing visit.
3. Em missão internacional do 5G, ministro visita sede da Ericsson e faz apelo por mais vacinas — Brazilian Government, February 4, 2021. Documents Faria's European 5G mission and his vaccine request through an investor connected to AstraZeneca.
4. Brazil regulator approves 5G spectrum auction rules, no Huawei ban — Reuters, February 25, 2021. Confirms Anatel approved commercial auction rules without restrictions on Huawei as an equipment supplier.
5. Ministro diz que empresa chinesa não cumpre requisitos para rede privativa de 5G do governo — Brazilian Chamber of Deputies, March 9, 2021. Establishes the distinction between Huawei's eligibility for the private government network and commercial 5G infrastructure.
6. China denies offer of 'vaccine diplomacy' deal to Paraguay — The Guardian, March 24, 2021. Documents Paraguay's allegation against unofficial brokers and the government's explicit qualification that their links to Beijing were unproven.
7. Foreign Ministry Spokesperson Hua Chunying's Regular Press Conference — Chinese Ministry of Foreign Affairs, March 24, 2021. Records Beijing's official denial of involvement in the alleged Paraguay arrangement.
8. Market Forces and Commercial Chinese Vaccine Sales — Pippa Morgan, Cambridge University Press, June 2023. Finds that approximately 90% of Chinese vaccine deliveries to the Global South during the first half of 2021 were commercial sales.
9. Help with strings attached? China's medical assistance and political allegiances during the Covid-19 pandemic — Angela Tritto, Hazwan Haini and Hongsen Wu, World Development, June 2024. Provides statistical evidence connecting Chinese medical assistance and vaccine distribution with recipients' political alignment on Hong Kong and Xinjiang.
10. China's mask and vaccine diplomacy in Latin America: a success story? — Detlef Nolte, International Politics, October 2023. Examines the limited geopolitical results of China's vaccine diplomacy and challenges the claim that vaccines caused Nicaragua's diplomatic switch.
11. Preserve, Pressure, Protect, and Peel: The US–China Rivalry and the Politics of Vaccine Provision — Rikio Inouye, International Studies Quarterly, February 2026. Provides country-level evidence of political patterns in Chinese vaccine distribution, including the Taiwan-recognition relationship and Nicaragua's subsequent vaccine deliveries.
12. Huawei or the US way? Why Brazil and South Africa did not securitize 5G — Janis van der Westhuizen, Revista Brasileira de Política Internacional, June 2024. Examines domestic political resistance to excluding Huawei and the possible influence of Chinese vaccine diplomacy.
13. WHO interim recommendations for Sinovac-CoronaVac — World Health Organization, first issued May 2021, updated March 2022. Provides the different efficacy endpoints and confidence intervals needed to assess the video's vaccine comparisons.
14. Pfizer and BioNTech Conclude Phase 3 Study — Pfizer, November 18, 2020. Documents the 95% efficacy result and the clinical-trial endpoint behind the Western vaccine comparison.